에 대한 최신 뉴스 HCW Biologics (NASDAQ:HCWB) 주식

HCW Biologics

HCW Biologics Inc is a clinical-stage biopharmaceutical company focused on discovering and developing novel immunotherapies to lengthen the health span by disrupting the link between chronic, low-grade inflammation and age-related diseases. The company has developed TOBI discovery platform, or Tissue factor-based fusion discovery platform, for the design of category-defining immunotherapeutic drugs. It has selected two molecules as its product candidate; HCW9218 and HCW9302. HCW9218 is a bifunctional immunotherapeutic designed with the capabilities to neutralize transforming growth and stimulate immune cells. HCW9302 is designed to activate and expand regulatory T cells, which deactivate inflammasomes.

HCW Biologics Inc

Cantor Fitzgerald analyst Olivia Brayer maintains Bristol-Myers Squibb (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BMY#NYSE">BMY</a>) with a Neutral and raises the price target from $50 to $55.

News

Price Target

Analyst Ratings

Cantor Fitzgerald Maintains Neutral on Bristol-Myers Squibb, Raises Price Target to $55

WIIM

Cardio Diagnostics Holdings Inc. - Common stock

CDIO

Cardio Diagnostics shares are trading higher after the company announced it partnered with seven new provider organizations to adopt its blood tests.

Riot Produces 527 Bitcoin in January 2025
CASTLE ROCK, Colo., Feb. 4, 2025 /PRNewswire/ -- Riot Platforms, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RIOT#NASDAQ">RIOT</a>) ("Riot" or "the Company"), an industry leader in vertically integrated Bitcoin ("BTC") mining, announces unaudited production and operations updates for January 2025.
Bitcoin Production and Operations Updates for January 2025
<figure class="table"> 
<table>
<tbody>
<tr>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="2" rowspan="1">Comparison (%)</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Metric</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1">January 2025 1</td>
<td colspan="1" rowspan="1">December 2024 1</td>
<td colspan="1" rowspan="1">January 2024</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1">Month/Month</td>
<td colspan="1" rowspan="1">Year/Year</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Bitcoin Produced</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1">527</td>
<td colspan="1" rowspan="1">516</td>
<td colspan="1" rowspan="1">520</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1">2&nbsp;%</td>
<td colspan="1" rowspan="1">1&nbsp;%</td>
</tr>
<tr>
<td colspan="2" rowspan="1">Average Bitcoin Produced per Day</td>
<td colspan="1" rowspan="1">17.0</td>
<td colspan="1" rowspan="1">16.6</td>
<td colspan="1" rowspan="1">16.8</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1">2&nbsp;%</td>
<td colspan="1" rowspan="1">1&nbsp;%</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Bitcoin Held 2</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1">18,221</td>
<td colspan="1" rowspan="1">17,722</td>
<td colspan="1" rowspan="1">7,648</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1">3&nbsp;%</td>
<td colspan="1" rowspan="1">138&nbsp;%</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Bitcoin Sold</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1">-</td>
<td colspan="1" rowspan="1">-</td>
<td colspan="1" rowspan="1">212</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1">N/A</td>
<td colspan="1" rowspan="1">N/A</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Bitcoin Sales - Net Proceeds</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1">-</td>
<td colspan="1" rowspan="1">-</td>
<td colspan="1" rowspan="1">$9.5 million</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1">N/A</td>
<td colspan="1" rowspan="1">N/A</td>
</tr>
<tr>
<td colspan="2" rowspan="1">Average Net Price per Bitcoin Sold</td>
<td colspan="1" rowspan="1">N/A</td>
<td colspan="1" rowspan="1">N/A</td>
<td colspan="1" rowspan="1">$44,860</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1">N/A</td>
<td colspan="1" rowspan="1">N/A</td>
</tr>
<tr>
<td colspan="2" rowspan="1">Deployed Hash Rate - Rockdale 2</td>
<td colspan="1" rowspan="1">15.0 EH/s</td>
<td colspan="1" rowspan="1">15.0 EH/s</td>
<td colspan="1" rowspan="1">12.4 EH/s</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1">0&nbsp;%</td>
<td colspan="1" rowspan="1">21&nbsp;%</td>
</tr>
<tr>
<td colspan="2" rowspan="1">Deployed Hash Rate - Corsicana 2</td>
<td colspan="1" rowspan="1">15.7 EH/s</td>
<td colspan="1" rowspan="1">14.1 EH/s</td>
<td colspan="1" rowspan="1">-</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1">11&nbsp;%</td>
<td colspan="1" rowspan="1">N/A</td>
</tr>
<tr>
<td colspan="2" rowspan="1">Deployed Hash Rate - Kentucky 2</td>
<td colspan="1" rowspan="1">2.8 EH/s</td>
<td colspan="1" rowspan="1">2.4 EH/s</td>
<td colspan="1" rowspan="1">N/A</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1">19&nbsp;%</td>
<td colspan="1" rowspan="1">N/A</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Deployed Hash Rate - Total 2</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1">33.5 EH/s</td>
<td colspan="1" rowspan="1">31.5 EH/s</td>
<td colspan="1" rowspan="1">12.4 EH/s</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1">6&nbsp;%</td>
<td colspan="1" rowspan="1">171&nbsp;%</td>
</tr>
<tr>
<td colspan="1" rowspan="1">
&nbsp;
&nbsp;Avg. Operating Hash Rate - Rockdale 4
&nbsp;
</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1">&nbsp;12.7 EH/s &nbsp;</td>
<td colspan="1" rowspan="1">&nbsp;12.1 EH/s&nbsp;</td>
<td colspan="1" rowspan="1">&nbsp;8.7 EH/s&nbsp;</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1">5&nbsp;%</td>
<td colspan="1" rowspan="1">47&nbsp;%</td>
</tr>
<tr>
<td colspan="2" rowspan="1">Avg. Operating Hash Rate - Corsicana 4</td>
<td colspan="1" rowspan="1">14.2 EH/s</td>
<td colspan="1" rowspan="1">13.1 EH/s</td>
<td colspan="1" rowspan="1">-</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1">8&nbsp;%</td>
<td colspan="1" rowspan="1">N/A</td>
</tr>
<tr>
<td colspan="2" rowspan="1">Avg. Operating Hash Rate - Kentucky 4</td>
<td colspan="1" rowspan="1">2.4 EH/s</td>
<td colspan="1" rowspan="1">2.2 EH/s</td>
<td colspan="1" rowspan="1">N/A</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1">10&nbsp;%</td>
<td colspan="1" rowspan="1">N/A</td>
</tr>
<tr>
<td colspan="2" rowspan="1">Avg. Operating Hash Rate - Total 4</td>
<td colspan="1" rowspan="1">29.3 EH/s</td>
<td colspan="1" rowspan="1">27.4 EH/s</td>
<td colspan="1" rowspan="1">8.7 EH/s</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1">7&nbsp;%</td>
<td colspan="1" rowspan="1">238&nbsp;%</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Power Credits 5</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1">$3.2 million</td>
<td colspan="1" rowspan="1">$0.8 million</td>
<td colspan="1" rowspan="1">$2.2 million</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1">328&nbsp;%</td>
<td colspan="1" rowspan="1">44&nbsp;%</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Demand Response Credits 6</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1">$0.4 million</td>
<td colspan="1" rowspan="1">$0.3 million</td>
<td colspan="1" rowspan="1">$1.1 million</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1">50&nbsp;%</td>
<td colspan="1" rowspan="1">-60&nbsp;%</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Total Power Credits</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1">$3.6 million</td>
<td colspan="1" rowspan="1">$1.0 million</td>
<td colspan="1" rowspan="1">$3.3 million</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1">250&nbsp;%</td>
<td colspan="1" rowspan="1">10&nbsp;%</td>
</tr>
<tr>
<td colspan="1" rowspan="1">All-in Power Cost - Rockdale 7</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1">3.3c/kWh</td>
<td colspan="1" rowspan="1">3.9c/kWh</td>
<td colspan="1" rowspan="1">3.3c/kWh</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1">-15&nbsp;%</td>
<td colspan="1" rowspan="1">0&nbsp;%</td>
</tr>
<tr>
<td colspan="2" rowspan="1">All-in Power Cost - Corsicana 7</td>
<td colspan="1" rowspan="1">
&nbsp;
&nbsp;3.7c/kWh
&nbsp;
</td>
<td colspan="1" rowspan="1">3.6c/kWh</td>
<td colspan="1" rowspan="1">N/A</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1">3&nbsp;%</td>
<td colspan="1" rowspan="1">N/A</td>
</tr>
<tr>
<td colspan="1" rowspan="1">All-in Power Cost - Kentucky 7</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1">3.2c/kWh8</td>
<td colspan="1" rowspan="1">4.6c/kWh</td>
<td colspan="1" rowspan="1">N/A</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1">-31&nbsp;%</td>
<td colspan="1" rowspan="1">N/A</td>
</tr>
<tr>
<td colspan="1" rowspan="1">All-in Power Cost - Total 7</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1">3.5c/kWh</td>
<td colspan="1" rowspan="1">3.8c/kWh</td>
<td colspan="1" rowspan="1">3.3c/kWh</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1">-8&nbsp;%</td>
<td colspan="1" rowspan="1">6&nbsp;%</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Fleet Efficiency 2</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1">21.1 J/TH</td>
<td colspan="1" rowspan="1">21.9 J/TH</td>
<td colspan="1" rowspan="1">27.0 J/TH</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1">-3&nbsp;%</td>
<td colspan="1" rowspan="1">-22&nbsp;%</td>
</tr>
</tbody>
</table>
</figure>

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

Markets

RIOT

Riot Announces January 2025 Production And Operations Updates; 527 Bitcoin Produced

President Donald Trump's <a href="https://www.benzinga.com/topic/tariffs">latest tariff moves</a> are shaking up global trade, but China may have a familiar counterstrike in mind. 
According to JPMorgan analyst Brian P. Ossenbeck, agricultural exports—particularly corn, wheat, and soybeans—are prime targets for Chinese retaliation. 
Any new developments on this front could be relevant to investors in the Teucrium Corn Fund (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CORN#NYSE">CORN</a>), the Teucrium Wheat Fund (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WEAT#NYSE">WEAT</a>) and the Teucrium Soybean Fund (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SOYB#NYSE">SOYB</a>).
With a history of leveraging tariffs to disrupt U.S. farm exports, Beijing could once again use this tactic to put pressure on American producers and policymakers.
Read Also: <a href="https://www.benzinga.com/analyst-ratings/analyst-color/25/02/43432736/copper-stocks-on-shaky-ground-jpmorgan-analysts-say-tariffs-deepseek-cloud-outlook">Copper Stocks On Shaky Ground, JPMorgan Analysts Say: Tariffs, DeepSeek Cloud Outlook</a>
<h2 class="wp-block-heading">A Familiar Playbook: Agriculture As A Pressure Point</h2>
Ossenbeck highlights that U.S. agricultural exports to China, especially soybeans, have been heavily impacted by past trade tensions. "A study by the U.S. Department of Agriculture found tariffs reduced U.S. agricultural exports by $27 billion in 2018-2019 and soybeans accounted for the majority of the decline at 71%." 
If history repeats itself, American farmers could face another round of painful disruptions.
<h2 class="wp-block-heading">Railroads On Alert</h2>
The impact of potential tariffs won't stop at the farms. U.S. rail giants like BNSF (2.5% exposure) and Union Pacific Corp (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UNP#NYSE">UNP</a>) (1% exposure) are directly tied to soybean exports and could feel the squeeze. 
Ossenbeck's analysis suggests that retaliatory tariffs on grains could weigh on transportation stocks, adding another layer of volatility to the already embattled Transports sector. Investors in the iShares US Transportation ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IYT#NYSE">IYT</a>) should remain wary of their holdings.
<h2 class="wp-block-heading">Trade Tensions Fuel Import Rush</h2>
Meanwhile, data from JPMorgan indicates that importers have been bracing for impact. Ossenbeck points to a "pull-forward of imports from China that started in 2H24 and appears to have continued into early 2025." 
January containerized imports hit an all-time record, signaling that businesses have been stockpiling goods ahead of expected tariffs.
<h2 class="wp-block-heading">A Volatile Road Ahead</h2>
While a 30-day delay on tariffs for Mexico and Canada brought temporary relief to markets, "we are hardly sounding the ‘all clear' after the first salvo in what could be a long and volatile trade war on multiple fronts," says Ossenbeck. 
Investors should stay alert, as China's next move could be just around the corner—potentially hitting U.S. agriculture where it hurts most.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/economics/macro-economic-events/25/02/43454424/china-strikes-back-new-tariffs-up-to-15-on-certain-us-imports-in-retaliation-for-trumps-10-levy-on-chinese-goods">China Strikes Back: New Tariffs Up To 15% On Certain US Imports In Retaliation For Trump&#8217;s 10% Levy On Chinese Goods</a></li>
</ul>
Image: Shutterstock

Analyst Color

Asia

Specialty ETFs

Commodities

ETFs

CORN

iShares Dow Jones Transportation Average Index Fund

SOYB

WEAT

China's Retaliatory Tariff Playbook: Corn, Wheat, Soybeans In The Crosshairs

Earnings

CLSK

CleanSpark In Jan. 2025 Produced 626 Bitcoin; Sold 22.47

SUPN

Supernus Receives FDA Approval Of ONAPGO Fr Parkinson's Disease

UnitedHealth Group (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UNH#NYSE">UNH</a>) has outperformed the market over the past 10 years by 6.34% on an annualized basis producing an average annual return of 17.53%. Currently, UnitedHealth Group has a market capitalization of $504.18 billion. 
Buying $100 In UNH: If an investor had bought $100 of UNH stock 10 years ago, it would be worth $514.77 today based on a price of $547.85 for UNH at the time of writing.
<h3>UnitedHealth Group's Performance Over Last 10 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1738677768_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Trading Ideas

Here's How Much $100 Invested In UnitedHealth Group 10 Years Ago Would Be Worth Today

CF Bankshares Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CFBK#NASDAQ">CFBK</a>) (the "Company"), the parent of CFBank, announced today that the Board of Directors of the Company has authorized a new stock repurchase program pursuant to which the Company may repurchase up to 325,000 shares, or approximately 5% of the Company's outstanding common stock, on or before January 31, 2026.&nbsp;&nbsp;Under the stock repurchase program, the Company may purchase shares of its common stock from time to time through various means, including open market transactions and privately negotiated transactions. Open market repurchases will be made in accordance with applicable securities laws and regulations, including Rule 10b-18 under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), and may be effected pursuant to Rule 10b5-1 under the Exchange Act. There is no guarantee as to the exact number or value of shares that will be repurchased by the Company.&nbsp; The manner, timing and amount of any stock repurchases will be determined by the Company's management in its discretion based on its evaluation of various factors, including the trading price of the Company's common stock, market and economic conditions, regulatory requirements and other corporate considerations. The repurchase program may be suspended or discontinued at any time.
 &nbsp;

Buybacks

CFBK

CF Bankshares Announces New Stock Repurchase Program For 325K Shares, 5% Of Outstanding Stock, By January 31, 2026

Management

BLNK

Blink Charing Appoints Mike Battaglia As President & CEO

Ratings for Twist Bioscience (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TWST#NASDAQ">TWST</a>) were provided by 6 analysts in the past three months, showcasing a mix of bullish and bearish perspectives.
The following table summarizes their recent ratings, shedding light on the changing sentiments within the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">1</td>
<td align="right">5</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">1</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts provide deeper insights through their assessments of 12-month price targets, revealing an average target of $54.33, a high estimate of $60.00, and a low estimate of $48.00. This upward trend is evident, with the current average reflecting a 5.7% increase from the previous average price target of $51.40.
<img src="https://www.benzinga.com/files/images/story/2025/1738677658_0.png" alt="price target chart" />
<h2>Deciphering Analyst Ratings: An In-Depth Analysis</h2>
An in-depth analysis of recent analyst actions unveils how financial experts perceive Twist Bioscience. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Catherine Ramsey</td>
<td>Baird</td>
<td>Raises</td>
<td>Outperform</td>
<td>$54.00</td>
<td>$48.00</td>
</tr>
<tr>
<td>Doug Schenkel</td>
<td>Wolfe Research</td>
<td>Announces</td>
<td>Outperform</td>
<td>$60.00</td>
<td>-</td>
</tr>
<tr>
<td>Steven Mah</td>
<td>TD Cowen</td>
<td>Maintains</td>
<td>Buy</td>
<td>$58.00</td>
<td>$58.00</td>
</tr>
<tr>
<td>Luke Sergott</td>
<td>Barclays</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$52.00</td>
<td>$55.00</td>
</tr>
<tr>
<td>Sung Ji Nam</td>
<td>Scotiabank</td>
<td>Raises</td>
<td>Sector Outperform</td>
<td>$54.00</td>
<td>$50.00</td>
</tr>
<tr>
<td>Catherine Ramsey</td>
<td>Baird</td>
<td>Raises</td>
<td>Outperform</td>
<td>$48.00</td>
<td>$46.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to Twist Bioscience. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Gaining insights, analysts provide qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of Twist Bioscience compared to the broader market.</li>
<li>Price Targets: Analysts explore the dynamics of price targets, providing estimates for the future value of Twist Bioscience's stock. This examination reveals shifts in analysts' expectations over time.</li>
</ul>
Navigating through these analyst evaluations alongside other financial indicators can contribute to a holistic understanding of Twist Bioscience's market standing. Stay informed and make data-driven decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/TWST/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Twist Bioscience analyst ratings.</a>
<h2>Discovering Twist Bioscience: A Closer Look</h2>
Twist Bioscience Corp is a synthetic biology company. It develops a disruptive DNA synthesis platform to industrialize the engineering of biology. The company's DNA synthesis platform utilizes a proprietary semiconductor-based synthetic DNA manufacturing process that synthesizes DNA on silicon instead of on traditional well-plastic plates to enable the production of high-quality synthetic DNA faster and affordable as well as overcomes inefficiencies and powers cost-effective, rapid high-throughput synthesis, enabling researchers to realize opportunities ahead rapidly. Geographically, it derives a majority of its revenue from the United States.
<h3>Twist Bioscience: Delving into Financials</h3>
Market Capitalization Analysis: Above industry benchmarks, the company's market capitalization emphasizes a noteworthy size, indicative of a strong market presence.
Revenue Growth: Twist Bioscience's revenue growth over a period of 3 months has been noteworthy. As of 30 September, 2024, the company achieved a revenue growth rate of approximately 26.53%. This indicates a substantial increase in the company's top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Health Care sector.
Net Margin: Twist Bioscience's net margin excels beyond industry benchmarks, reaching -40.91%. This signifies efficient cost management and strong financial health.
Return on Equity (ROE): Twist Bioscience's financial strength is reflected in its exceptional ROE, which exceeds industry averages. With a remarkable ROE of -7.19%, the company showcases efficient use of equity capital and strong financial health.
Return on Assets (ROA): Twist Bioscience's ROA is below industry averages, indicating potential challenges in efficiently utilizing assets. With an ROA of -5.53%, the company may face hurdles in achieving optimal financial returns.
Debt Management: Twist Bioscience's debt-to-equity ratio is below industry norms, indicating a sound financial structure with a ratio of 0.18.
<h2>Analyst Ratings: What Are They?</h2>
Analysts are specialists within banking and financial systems that typically report for specific stocks or within defined sectors. These people research company financial statements, sit in conference calls and meetings, and speak with relevant insiders to determine what are known as analyst ratings for stocks. Typically, analysts will rate each stock once a quarter. 
Beyond their standard evaluations, some analysts contribute predictions for metrics like growth estimates, earnings, and revenue, furnishing investors with additional guidance. Users of analyst ratings should be mindful that this specialized advice is shaped by human perspectives and may be subject to variability.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;utm_source=benzinga-insights">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

TWST

Forecasting The Future: 6 Analyst Projections For Twist Bioscience

PayPal Holdings Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PYPL#NASDAQ">PYPL</a>) <a target="_blank" href="https://www.benzinga.com/topic/paypal" rel="noreferrer noopener">reported fiscal fourth-quarter</a> revenue growth of 4% year over year to $8.37 billion, topping the&nbsp;analyst consensus estimate <a target="_blank" href="https://investor.pypl.com/financials/quarterly-results/default.aspx" rel="noreferrer noopener">of&nbsp;$8.26 billion</a>.&nbsp;
The company reported an adjusted EPS of $1.19, beating&nbsp;the <a target="_blank" href="https://www.benzinga.com/calendars/earnings" rel="noreferrer noopener">analyst consensus estimate of $1.12</a>. The stock dipped after the print.
Also Read: <a target="_blank" href="https://www.benzinga.com/government/regulations/25/02/43458397/sam-altman-in-korea-openai-seeks-ai-deals-with-samsung-sk-hynix-and-softbank-amid-global-ai-boom" rel="noreferrer noopener">Sam Altman in Korea: OpenAI Seeks AI Deals With Samsung, SK Hynix, and SoftBank Amid Global AI Boom</a>
Total payment volumes increased 7% year-over-year to $437.8 billion in the quarter. Payment transactions were down 3% to $6.6 billion, and the payment transactions per active account increased 3% on a trailing 12-month basis to $60.6.
Total active accounts&nbsp;increased by 2.1% to 434 million. On a sequential basis, active accounts increased by 0.6%, or 2.6 million.
The operating margin declined 431 basis points to 17.2%, and the adjusted operating margin decreased 34 bps to 18.0%.
Operating cash flow&nbsp;was&nbsp;$2.4 billion, and free cash flow&nbsp;was&nbsp;$2.2 billion.&nbsp;PayPal held $15.4 billion in cash and equivalents as of December 31, 2024, and had a debt of $11.1 billion on its balance sheet.
Buyback: PayPal&#8217;s Board approved a new $15 billion stock repurchase program.
CEO Alex Chriss flagged improvements to branded checkout, peer-to-peer, and Venmo, plus the progress to its price-to-value strategy behind the quarterly print.
Outlook: PayPal expects first-quarter adjusted EPS of $1.15-$1.17, compared to $1.08 for the previous year&#8217;s period and the <a target="_blank" href="https://www.benzinga.com/calendars/guidance" rel="noreferrer noopener">consensus of $1.13</a>.
PayPal expects full-year 2024 adjusted EPS of $4.95-$5.10, compared to $4.65 Y/Y.&nbsp;Current analyst estimates&nbsp;call for an EPS of $4.90.
PayPal stock surged over 45% in the last 12 months. At least <a target="_blank" href="https://www.benzinga.com/quote/PYPL/analyst-ratings" rel="noreferrer noopener">four Wall Street firms</a>, including Susquehanna, Citigroup, Wells Fargo, and Piper Sandler, raised their price targets on the stock in January 2025.
Price Action: At&nbsp;the last check on Tuesday, PYPL stock was down 8.02% at $82.33 premarket.
Also Read:
<ul>
<li><a href="https://www.benzinga.com/25/02/43444802/comcast-downgraded-as-broadband-struggles-and-price-cuts-raise-investor-concerns" target="_blank" rel="noreferrer noopener">Comcast Faces Broadband Headwinds, Analyst Downgrades Stock And Cuts Price Forecast</a></li>
</ul>

Guidance

PYPL

PayPal Q4 Earnings: Revenue And EPS Beat, Margin Pressure, $15 Billion Buyback, Outlook And More

During the last three months, 10 analysts shared their evaluations of Ralph Lauren (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RL#NYSE">RL</a>), revealing diverse outlooks from bullish to bearish.
The following table provides a quick overview of their recent ratings, highlighting the changing sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">5</td>
<td align="right">4</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">2</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
The 12-month price targets, analyzed by analysts, offer insights with an average target of $265.2, a high estimate of $335.00, and a low estimate of $207.00. Witnessing a positive shift, the current average has risen by 6.29% from the previous average price target of $249.50.
<img src="https://www.benzinga.com/files/images/story/2025/1738677650_0.png" alt="price target chart" />
<h2>Deciphering Analyst Ratings: An In-Depth Analysis</h2>
A clear picture of Ralph Lauren's perception among financial experts is painted with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Dana Telsey</td>
<td>Telsey Advisory Group</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$265.00</td>
<td>$265.00</td>
</tr>
<tr>
<td>Robert Drbul</td>
<td>Guggenheim</td>
<td>Raises</td>
<td>Buy</td>
<td>$285.00</td>
<td>$260.00</td>
</tr>
<tr>
<td>Ashley Helgans</td>
<td>Jefferies</td>
<td>Raises</td>
<td>Buy</td>
<td>$285.00</td>
<td>$280.00</td>
</tr>
<tr>
<td>Jay Sole</td>
<td>UBS</td>
<td>Raises</td>
<td>Buy</td>
<td>$335.00</td>
<td>$315.00</td>
</tr>
<tr>
<td>Ike Boruchow</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$225.00</td>
<td>$215.00</td>
</tr>
<tr>
<td>Adrienne Yih</td>
<td>Barclays</td>
<td>Raises</td>
<td>Overweight</td>
<td>$257.00</td>
<td>$200.00</td>
</tr>
<tr>
<td>Rick Patel</td>
<td>Raymond James</td>
<td>Raises</td>
<td>Outperform</td>
<td>$235.00</td>
<td>$215.00</td>
</tr>
<tr>
<td>Jay Sole</td>
<td>UBS</td>
<td>Raises</td>
<td>Buy</td>
<td>$300.00</td>
<td>$287.00</td>
</tr>
<tr>
<td>John Kernan</td>
<td>TD Cowen</td>
<td>Raises</td>
<td>Buy</td>
<td>$258.00</td>
<td>$251.00</td>
</tr>
<tr>
<td>Dana Telsey</td>
<td>Telsey Advisory Group</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$207.00</td>
<td>$207.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to Ralph Lauren. This offers insight into analysts' perspectives on the current state of the company.</li>
<li>Rating: Analyzing trends, analysts offer qualitative evaluations, ranging from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Ralph Lauren compared to the broader market.</li>
<li>Price Targets: Analysts provide insights into price targets, offering estimates for the future value of Ralph Lauren's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
Capture valuable insights into Ralph Lauren's market standing by understanding these analyst evaluations alongside pertinent financial indicators. Stay informed and make strategic decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/RL/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Ralph Lauren analyst ratings.</a>
<h2>Get to Know Ralph Lauren Better</h2>
Founded by designer Ralph Lauren in 1967 in New York City, Ralph Lauren Corp. designs, markets, and distributes lifestyle merchandise in North America, Europe, and Asia. Best known for its iconic polo shirts, its products also include other types of apparel, footwear, eyewear, jewelry, handbags, home goods, and fragrances. The company's brands include Ralph Lauren Collection, Polo Ralph Lauren, and Lauren Ralph Lauren. Distribution channels for Ralph Lauren include wholesale (department stores and specialty stores), retail (company-owned retail stores and e-commerce), and licensing.
<h3>Financial Insights: Ralph Lauren</h3>
Market Capitalization Highlights: Above the industry average, the company's market capitalization signifies a significant scale, indicating strong confidence and market prominence.
Revenue Growth: Ralph Lauren's remarkable performance in 3 months is evident. As of 30 September, 2024, the company achieved an impressive revenue growth rate of 5.7%. This signifies a substantial increase in the company's top-line earnings. When compared to others in the Consumer Discretionary sector, the company excelled with a growth rate higher than the average among peers.
Net Margin: Ralph Lauren's net margin excels beyond industry benchmarks, reaching 8.57%. This signifies efficient cost management and strong financial health.
Return on Equity (ROE): Ralph Lauren's ROE stands out, surpassing industry averages. With an impressive ROE of 6.15%, the company demonstrates effective use of equity capital and strong financial performance.
Return on Assets (ROA): Ralph Lauren's ROA excels beyond industry benchmarks, reaching 2.2%. This signifies efficient management of assets and strong financial health.
Debt Management: Ralph Lauren's debt-to-equity ratio is below the industry average. With a ratio of 1.09, the company relies less on debt financing, maintaining a healthier balance between debt and equity, which can be viewed positively by investors.
<h2>How Are Analyst Ratings Determined?</h2>
Analysts are specialists within banking and financial systems that typically report for specific stocks or within defined sectors. These people research company financial statements, sit in conference calls and meetings, and speak with relevant insiders to determine what are known as analyst ratings for stocks. Typically, analysts will rate each stock once a quarter. 
Beyond their standard evaluations, some analysts contribute predictions for metrics like growth estimates, earnings, and revenue, furnishing investors with additional guidance. Users of analyst ratings should be mindful that this specialized advice is shaped by human perspectives and may be subject to variability.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;utm_source=benzinga-insights">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Expert Outlook: Ralph Lauren Through The Eyes Of 10 Analysts

In the latest quarter, 4 analysts provided ratings for Blink Charging (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BLNK#NASDAQ">BLNK</a>), showcasing a mix of bullish and bearish perspectives.
The table below offers a condensed view of their recent ratings, showcasing the changing sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts have set 12-month price targets for Blink Charging, revealing an average target of $2.55, a high estimate of $5.00, and a low estimate of $1.50. Observing a downward trend, the current average is 21.54% lower than the prior average price target of $3.25. 
<img src="https://www.benzinga.com/files/images/story/2025/1738677640_0.png" alt="price target chart" />
<h2>Interpreting Analyst Ratings: A Closer Look</h2>
A clear picture of Blink Charging's perception among financial experts is painted with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Christine Cho</td>
<td>Barclays</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$1.50</td>
<td>$3.00</td>
</tr>
<tr>
<td>William Grippin</td>
<td>UBS</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$1.70</td>
<td>$2.00</td>
</tr>
<tr>
<td>William Grippin</td>
<td>UBS</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$2.00</td>
<td>$3.00</td>
</tr>
<tr>
<td>Michael Legg</td>
<td>Benchmark</td>
<td>Maintains</td>
<td>Buy</td>
<td>$5.00</td>
<td>$5.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to Blink Charging. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Analyzing trends, analysts offer qualitative evaluations, ranging from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Blink Charging compared to the broader market.</li>
<li>Price Targets: Gaining insights, analysts provide estimates for the future value of Blink Charging's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
Analyzing these analyst evaluations alongside relevant financial metrics can provide a comprehensive view of Blink Charging's market position. Stay informed and make data-driven decisions with the assistance of our Ratings Table.
<a href="https://www.benzinga.com/quote/BLNK/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Blink Charging analyst ratings.</a>
If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap">you can start by tracking it here</a>.
<h2>Discovering Blink Charging: A Closer Look</h2>
Blink Charging Co is an owner, operator, and provider of electric vehicle (EV) charging services. The company offers both residential and commercial EV charging equipment, enabling EV drivers to easily recharge at various location types. The company's business is the sale and distribution of electric vehicle charging equipment and its associated revenues earned from customers and/or Property Partners who use equipment connected to its network. It earns majority revenue from U.S.A.
<h3>Blink Charging: Delving into Financials</h3>
Market Capitalization Analysis: Positioned below industry benchmarks, the company's market capitalization faces constraints in size. This could be influenced by factors such as growth expectations or operational capacity.
Revenue Growth: Blink Charging's revenue growth over a period of 3 months has faced challenges. As of 30 September, 2024, the company experienced a revenue decline of approximately -44.14%. This indicates a decrease in the company's top-line earnings. When compared to others in the Industrials sector, the company faces challenges, achieving a growth rate lower than the average among peers.
Net Margin: Blink Charging's net margin is impressive, surpassing industry averages. With a net margin of -361.04%, the company demonstrates strong profitability and effective cost management.
Return on Equity (ROE): Blink Charging's ROE is below industry standards, pointing towards difficulties in efficiently utilizing equity capital. With an ROE of -36.96%, the company may encounter challenges in delivering satisfactory returns for shareholders.
Return on Assets (ROA): The company's ROA is below industry benchmarks, signaling potential difficulties in efficiently utilizing assets. With an ROA of -25.58%, the company may need to address challenges in generating satisfactory returns from its assets.
Debt Management: The company maintains a balanced debt approach with a debt-to-equity ratio below industry norms, standing at 0.06.
<h2>Analyst Ratings: Simplified</h2>
Within the domain of banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their work involves attending company conference calls and meetings, researching company financial statements, and communicating with insiders to publish "analyst ratings" for stocks. Analysts typically assess and rate each stock once per quarter.
Analysts may supplement their ratings with predictions for metrics like growth estimates, earnings, and revenue, offering investors a more comprehensive outlook. However, investors should be mindful that analysts, like any human, can have subjective perspectives influencing their forecasts.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;utm_source=benzinga-insights">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Analyst Expectations For Blink Charging's Future

VICI Props (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VICI#NYSE">VICI</a>) underwent analysis by 8 analysts in the last quarter, revealing a spectrum of viewpoints from bullish to bearish.
The table below offers a condensed view of their recent ratings, showcasing the changing sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">1</td>
<td align="right">7</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">1</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts' evaluations of 12-month price targets offer additional insights, showcasing an average target of $34.0, with a high estimate of $36.00 and a low estimate of $30.00. This current average has decreased by 3.66% from the previous average price target of $35.29. 
<img src="https://www.benzinga.com/files/images/story/2025/1738677633_0.png" alt="price target chart" />
<h2>Analyzing Analyst Ratings: A Detailed Breakdown</h2>
In examining recent analyst actions, we gain insights into how financial experts perceive VICI Props. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Richard Hightower</td>
<td>Barclays</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$35.00</td>
<td>$36.00</td>
</tr>
<tr>
<td>Greg Miller</td>
<td>JMP Securities</td>
<td>Maintains</td>
<td>Market Outperform</td>
<td>$35.00</td>
<td>$35.00</td>
</tr>
<tr>
<td>Barry Jonas</td>
<td>Truist Securities</td>
<td>Lowers</td>
<td>Buy</td>
<td>$35.00</td>
<td>$40.00</td>
</tr>
<tr>
<td>Richard Hightower</td>
<td>Barclays</td>
<td>Announces</td>
<td>Overweight</td>
<td>$36.00</td>
<td>-</td>
</tr>
<tr>
<td>Haendel St. Juste</td>
<td>Mizuho</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$30.00</td>
<td>$33.00</td>
</tr>
<tr>
<td>Richard Anderson</td>
<td>Wedbush</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$33.00</td>
<td>$34.00</td>
</tr>
<tr>
<td>Mitch Germain</td>
<td>JMP Securities</td>
<td>Maintains</td>
<td>Market Outperform</td>
<td>$35.00</td>
<td>$35.00</td>
</tr>
<tr>
<td>Haendel St. Juste</td>
<td>Mizuho</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$33.00</td>
<td>$34.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to VICI Props. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Analyzing trends, analysts offer qualitative evaluations, ranging from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of VICI Props compared to the broader market.</li>
<li>Price Targets: Analysts provide insights into price targets, offering estimates for the future value of VICI Props's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
Understanding these analyst evaluations alongside key financial indicators can offer valuable insights into VICI Props's market standing. Stay informed and make well-considered decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/VICI/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on VICI Props analyst ratings.</a>
<h2>Get to Know VICI Props Better</h2>
VICI Properties Inc is a real estate investment trust based in the United States. It engaged in the business of owning and acquiring gaming, hospitality, and entertainment destinations, subject to long-term triple net leases. The company's operating segments are real property business and golf course business. The Real property business segment consists of leased real property whereas the Golf course business segment consists of several golf courses. Its golf courses include the Cascata Golf Course, the Rio Secco Golf Course, the Grand Bear Golf Course, and the Chariot Run Golf Course.
<h3>Financial Milestones: VICI Props's Journey</h3>
Market Capitalization: Boasting an elevated market capitalization, the company surpasses industry averages. This signals substantial size and strong market recognition.
Revenue Growth: VICI Props's remarkable performance in 3 months is evident. As of 30 September, 2024, the company achieved an impressive revenue growth rate of 6.67%. This signifies a substantial increase in the company's top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Real Estate sector.
Net Margin: VICI Props's net margin excels beyond industry benchmarks, reaching 75.97%. This signifies efficient cost management and strong financial health.
Return on Equity (ROE): VICI Props's ROE excels beyond industry benchmarks, reaching 2.83%. This signifies robust financial management and efficient use of shareholder equity capital.
Return on Assets (ROA): VICI Props's ROA stands out, surpassing industry averages. With an impressive ROA of 1.64%, the company demonstrates effective utilization of assets and strong financial performance.
Debt Management: The company maintains a balanced debt approach with a debt-to-equity ratio below industry norms, standing at 0.68.
<h2>Understanding the Relevance of Analyst Ratings</h2>
Analyst ratings serve as essential indicators of stock performance, provided by experts in banking and financial systems. These specialists diligently analyze company financial statements, participate in conference calls, and engage with insiders to generate quarterly ratings for individual stocks.
Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;utm_source=benzinga-insights">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

VICI

Where VICI Props Stands With Analysts

In the latest quarter, 6 analysts provided ratings for Essential Props Realty (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EPRT#NYSE">EPRT</a>), showcasing a mix of bullish and bearish perspectives.
The table below provides a concise overview of recent ratings by analysts, offering insights into the changing sentiments over the past 30 days and drawing comparisons with the preceding months for a holistic perspective.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">2</td>
<td align="right">3</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Insights from analysts' 12-month price targets are revealed, presenting an average target of $36.16, a high estimate of $40.00, and a low estimate of $33.00. This upward trend is apparent, with the current average reflecting a 4.81% increase from the previous average price target of $34.50.
<img src="https://www.benzinga.com/files/images/story/2025/1738677624_0.png" alt="price target chart" />
<h2>Exploring Analyst Ratings: An In-Depth Overview</h2>
The perception of Essential Props Realty by financial experts is analyzed through recent analyst actions. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Richard Hightower</td>
<td>Barclays</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$35.00</td>
<td>$36.00</td>
</tr>
<tr>
<td>Richard Hightower</td>
<td>Barclays</td>
<td>Announces</td>
<td>Overweight</td>
<td>$35.94</td>
<td>-</td>
</tr>
<tr>
<td>Omotayo Okusanya</td>
<td>Deutsche Bank</td>
<td>Announces</td>
<td>Buy</td>
<td>$38.00</td>
<td>-</td>
</tr>
<tr>
<td>Greg McGinniss</td>
<td>Scotiabank</td>
<td>Raises</td>
<td>Sector Perform</td>
<td>$33.00</td>
<td>$32.00</td>
</tr>
<tr>
<td>Michael Goldsmith</td>
<td>UBS</td>
<td>Raises</td>
<td>Buy</td>
<td>$40.00</td>
<td>$39.00</td>
</tr>
<tr>
<td>Vikram Malhorta</td>
<td>Mizuho</td>
<td>Raises</td>
<td>Outperform</td>
<td>$35.00</td>
<td>$31.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to Essential Props Realty. This insight gives a snapshot of analysts' perspectives on the current state of the company.</li>
<li>Rating: Unveiling insights, analysts deliver qualitative insights into stock performance, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Essential Props Realty compared to the broader market.</li>
<li>Price Targets: Analysts set price targets as an estimate of a stock's future value. Comparing the current and prior price targets provides insight into how analysts' expectations have changed over time. This information can be valuable for investors seeking to understand consensus views on the stock's potential future performance.</li>
</ul>
Navigating through these analyst evaluations alongside other financial indicators can contribute to a holistic understanding of Essential Props Realty's market standing. Stay informed and make data-driven decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/EPRT/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Essential Props Realty analyst ratings.</a>
<h2>All You Need to Know About Essential Props Realty</h2>
Essential Properties Realty Trust Inc is a real estate investment trust. It is an internally managed real estate company acquires, owns and manages single-tenant properties that are net leased on a long-term basis to middle-market companies operating service-oriented or experience-based businesses.
<h3>Unraveling the Financial Story of Essential Props Realty</h3>
Market Capitalization Analysis: With an elevated market capitalization, the company stands out above industry averages, showcasing substantial size and market acknowledgment.
Revenue Growth: Over the 3 months period, Essential Props Realty showcased positive performance, achieving a revenue growth rate of 27.79% as of 30 September, 2024. This reflects a substantial increase in the company's top-line earnings. In comparison to its industry peers, the company stands out with a growth rate higher than the average among peers in the Real Estate sector.
Net Margin: Essential Props Realty's financial strength is reflected in its exceptional net margin, which exceeds industry averages. With a remarkable net margin of 41.85%, the company showcases strong profitability and effective cost management.
Return on Equity (ROE): Essential Props Realty's financial strength is reflected in its exceptional ROE, which exceeds industry averages. With a remarkable ROE of 1.52%, the company showcases efficient use of equity capital and strong financial health.
Return on Assets (ROA): The company's ROA is a standout performer, exceeding industry averages. With an impressive ROA of 0.91%, the company showcases effective utilization of assets.
Debt Management: Essential Props Realty's debt-to-equity ratio is below industry norms, indicating a sound financial structure with a ratio of 0.69.
<h2>How Are Analyst Ratings Determined?</h2>
Benzinga tracks 150 analyst firms and reports on their stock expectations. Analysts typically arrive at their conclusions by predicting how much money a company will make in the future, usually the upcoming five years, and how risky or predictable that company's revenue streams are.
Analysts attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish their ratings on stocks. Analysts typically rate each stock once per quarter or whenever the company has a major update.
Some analysts also offer predictions for helpful metrics such as earnings, revenue, and growth estimates to provide further guidance as to what to do with certain tickers. It is important to keep in mind that while stock and sector analysts are specialists, they are also human and can only forecast their beliefs to traders.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;utm_source=benzinga-insights">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

EPRT

Expert Outlook: Essential Props Realty Through The Eyes Of 6 Analysts

Providing a diverse range of perspectives from bullish to bearish, 4 analysts have published ratings on W.P. Carey (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WPC#NYSE">WPC</a>) in the last three months.
In the table below, you'll find a summary of their recent ratings, revealing the shifting sentiments over the past 30 days and comparing them to the previous months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">2</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts provide deeper insights through their assessments of 12-month price targets, revealing an average target of $58.5, a high estimate of $60.00, and a low estimate of $56.00. A 1.27% drop is evident in the current average compared to the previous average price target of $59.25. 
<img src="https://www.benzinga.com/files/images/story/2025/1738677612_0.png" alt="price target chart" />
<h2>Breaking Down Analyst Ratings: A Detailed Examination</h2>
The standing of W.P. Carey among financial experts is revealed through an in-depth exploration of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Rich Hightower</td>
<td>Barclays</td>
<td>Lowers</td>
<td>Underweight</td>
<td>$56.00</td>
<td>$59.00</td>
</tr>
<tr>
<td>Nicholas Yulico</td>
<td>Scotiabank</td>
<td>Lowers</td>
<td>Sector Perform</td>
<td>$59.00</td>
<td>$60.00</td>
</tr>
<tr>
<td>Rich Hightower</td>
<td>Barclays</td>
<td>Raises</td>
<td>Underweight</td>
<td>$59.00</td>
<td>$56.00</td>
</tr>
<tr>
<td>Michael Goldsmith</td>
<td>UBS</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$60.00</td>
<td>$62.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to W.P. Carey. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Gaining insights, analysts provide qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of W.P. Carey compared to the broader market.</li>
<li>Price Targets: Analysts set price targets as an estimate of a stock's future value. Comparing the current and prior price targets provides insight into how analysts' expectations have changed over time. This information can be valuable for investors seeking to understand consensus views on the stock's potential future performance.</li>
</ul>
Capture valuable insights into W.P. Carey's market standing by understanding these analyst evaluations alongside pertinent financial indicators. Stay informed and make strategic decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/WPC/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on W.P. Carey analyst ratings.</a>
<h2>Discovering W.P. Carey: A Closer Look</h2>
W.P. Carey Inc is a real estate investment trust principally involved in the ownership of properties located in the U.S., Western Europe, and Northern Europe. W.P. Carey organizes its operations into Real Estate and Investment Management segments. The vast majority of the company's income is derived from its Real Estate division in the form of lease revenue from long-term agreements with companies. W.P. Carey's real estate portfolio is primarily comprised of single-tenant office, industrial, warehouse, and retail facilities located around the world. most of the company's revenue comes from properties in the USA. The company's Investment Management unit generates revenue from providing real estate advisory and portfolio management services to other REITs.
<h3>W.P. Carey: A Financial Overview</h3>
Market Capitalization Analysis: With an elevated market capitalization, the company stands out above industry averages, showcasing substantial size and market acknowledgment.
Negative Revenue Trend: Examining W.P. Carey's financials over 3 months reveals challenges. As of 30 September, 2024, the company experienced a decline of approximately -11.41% in revenue growth, reflecting a decrease in top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Real Estate sector.
Net Margin: W.P. Carey's financial strength is reflected in its exceptional net margin, which exceeds industry averages. With a remarkable net margin of 28.11%, the company showcases strong profitability and effective cost management.
Return on Equity (ROE): W.P. Carey's ROE excels beyond industry benchmarks, reaching 1.3%. This signifies robust financial management and efficient use of shareholder equity capital.
Return on Assets (ROA): W.P. Carey's ROA surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 0.63% ROA, the company effectively utilizes its assets for optimal returns.
Debt Management: W.P. Carey's debt-to-equity ratio is below the industry average. With a ratio of 0.93, the company relies less on debt financing, maintaining a healthier balance between debt and equity, which can be viewed positively by investors.
<h2>How Are Analyst Ratings Determined?</h2>
Experts in banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their comprehensive research involves attending company conference calls and meetings, analyzing financial statements, and engaging with insiders to generate what are known as analyst ratings for stocks. Typically, analysts assess and rate each stock once per quarter.
Analysts may supplement their ratings with predictions for metrics like growth estimates, earnings, and revenue, offering investors a more comprehensive outlook. However, investors should be mindful that analysts, like any human, can have subjective perspectives influencing their forecasts.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;utm_source=benzinga-insights">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Assessing W.P. Carey: Insights From 4 Financial Analysts

VLCN

Volcan shares are trading higher after the company announced an agreement to be the exclusive distributor of Super Sonic golf carts.

Cantor Fitzgerald analyst Matthew Prisco reiterates NXP Semiconductors (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NXPI#NASDAQ">NXPI</a>) with a Overweight and maintains $250 price target.

Reiteration

NXPI

Cantor Fitzgerald Reiterates Overweight on NXP Semiconductors, Maintains $250 Price Target

PepsiCo CEO Says Co Has Not Seen Direct Impact Of GLP-1 Drugs

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our <a href="https://www.benzinga.com/analyst-stock-ratings">analyst ratings page</a>.
<ul>
<li>Piper Sandler analyst David Amsellem downgraded Amphastar Pharmaceuticals, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMPH#NASDAQ">AMPH</a>) from Overweight to Neutral and lowered the price target from $66 to $36. Amphastar Pharma shares closed at $33.39 on Monday. <a href="https://www.benzinga.com/quote/AMPH/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Baird analyst Peter Arment downgraded Triumph Group, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TGI#NYSE">TGI</a>) from Outperform to Neutral but raised the price target from $20 to $26. Triumph Group shares closed at $25.10 on Monday. <a href="https://www.benzinga.com/quote/TTGI/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Jefferies analyst Randal Konik downgraded the rating for Ollie&#8217;s Bargain Outlet Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OLLI#NASDAQ">OLLI</a>) from Buy to Hold and lowered the price target from $125 to $111. Ollie&#8217;s Bargain shares closed at $107.63 on Monday. <a href="https://www.benzinga.com/quote/OLLI/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>UBS analyst Manav Gupta downgraded Calumet, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CLMT#NASDAQ">CLMT</a>) from Neutral to Sell and cut the price target from $20.5 to $15. Calumet shares closed at $18.34 on Monday. <a href="https://www.benzinga.com/quote/CLMT/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Wolfe Research analyst Trevor Allinson downgraded the rating for American Woodmark Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMWD#NASDAQ">AMWD</a>) from Outperform to Peer Perform. American Woodmark shares closed at $75.65 on Monday. <a href="https://www.benzinga.com/quote/AMWD/analyst-ratings">See how other analysts view this stock.</a></li>
</ul>
Considering buying OLLI stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image size-large is-resized"><img loading="lazy" decoding="async" width="1024" height="628" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/04085758/image-23-1024x628.png" alt="" class="wp-image-764859" style="width:568px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/04085758/image-23-1024x628.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/04085758/image-23-300x184.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/04085758/image-23-768x471.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/04085758/image-23.png 1077w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>

Downgrades

Pre-Market Outlook

AMPH

AMWD

CLMT

OLLI

This Ollie's Bargain Outlet Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Tuesday

HCW Biologics reports Q3 results

HCW Biologics jumps on license agreement for immunotherapeutic product candidate

HCW Biologics (HCWB) and WY Biotech, a China-based company specializing in the early-stage development of recombinant protein drugs and gene/cell t...

HCW Biologics licenses proprietary preclinical molecule to WY Biotech

HCW Biologics (HCWB) "announced that it has entered into a securities purchase agreement with a single institutional investor to purchase 6,717,000...

HCW Biologics prices $6.9M registered direct offering at $1.03 per share

HCW Biologics announces pricing of $6.9M registered direct offering, concurrent private placement

HCW Biologics ( ($HCWB) ) has issued an announcement. HCW Biologics Inc. has entered a $6.9 million securities purchase agreement with an instituti...

HCW Biologics Expands with New Financial Agreements

Michael Okunewitch, an analyst from Maxim Group, maintained the Buy rating on HCW Biologics (HCWB – Research Report). The associated price target i...

HCW Biologics Secures Strategic Agreements and Funding to Propel Growth and Innovation

HCW Biologics (HCWB) reported on December 17, 2024, the Company received written notice from the Listing Qualifications Staff that it had failed to...

HCW Biologics receives notice on failing to regain compliance from Nasdaq

HCW Biologics (HCWB) announced that Hing Wong, PhD., Founder and CEO, will serve as a panelist on Panel Discussion II of the 2025 GenScript Biotech...

HCW Biologics CEO to address opportunities, challenges in biomanufacturing

HCW Biologics ( ($HCWB) ) has shared an announcement. On February 3, 2025, HCW Biologics announced that the FDA has cleared its Investigational New...

HCW Biologics Advances with FDA Clearance for Trial

HCWB

Press Releases

HCW Biologics Reports Fourth Quarter 2023 and Fiscal Year End Financial Results And Business Highlights

HCW Biologics Reports First Quarter 2024 Financial Results and Business Highlights

HCW Biologics Reports Second Quarter 2024 Financial Results and Business Highlights

HCW Biologics Reports Third Quarter 2024 Financial Results and Business Highlights

HCW Biologics and WY Biotech Announce License Agreement  for Immunotherapeutic Product Candidate

Spotlight on Undervalued Nasdaq Stocks: HCWB, CRDL, NIVF, SINT, APLM – A Must-Watch This Week!

IPOs

HCW Biologics Announces Pricing of $6.9 Million Registered Direct Offering and Concurrent Private Placement Priced Above Market Under NASDAQ Rules

HCW Biologics Inc. Received NASDAQ Staff Determination Letter

HCW Biologics' Founder and CEO to Address Opportunities and Challenges in Biomanufacturing for Cell and Gene Therapies During J.P. Morgan Week in San Francisco on January 15, 2025

Comments

HCW Biologics

뉴스

에 대한 최신 뉴스 HCW Biologics (NASDAQ:HCWB) 주식

사람들이 또한 지켜본다

뉴스

파트너 / 기고자

벤징가 글로벌